Company Overview
Company Type: Private Company
Website: www.feldan.com
Number of Employees: 26
Year Founded: 1999
Total Amount Raised (CAD mm)†: 37.72
Total Rounds of Funding**:6
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Feldan Bio Inc., a recombinant protein company, discovers, develops, manufactures, and markets recombinant proteins and molecular biology reagents for life science companies and research laboratories in the United States, Canada, Europe, and internationally. The company develops Feldan Shuttle, a protein-based technology platform that delivers transcription factors and genome editing tools in clinical applications. It also provides Anti-AFP, a mouse monoclonal antibody; B-Cell culture supplement; FastFect, a transfection reagent; Hybridoma cloning booster; Hybridoma fusion and cloning booster; Hybridoma fusion booster; recombinant fibroblast growth factor-2; recombinant human epidermal growth factor; cell culture products, chemokines, cytokines and growth factors, enzymes, hormones, infectious agents proteins, receptors, specialty proteins, and toxins; and molecular biology kits used to isolate, manipulate, and amplify DNA. In addition, it offers research protein products for universities and medical institutions, contract manufacturing organizations, life science companies, government agencies, pharmaceuticals manufacturers, and biotechnology research organizations; and develops and licenses therapeutic proteins for biotech industry newcomers that manufacture and commercialize biopharmaceuticals for the treatment of various diseases, including cancer, diabetes, hepatitis, or multiple sclerosis. Further, the company provides protein expression, antibody generation, process development, custom peptide synthesis, adenovirus generation, lentivirus generation, and molecular biology custom services. Furthermore, it offers recombinant Cas9-NLS that includes Cas9 protein sequence (1368 amino acids) fused to a 6 X His tag and a nuclear localization sequence (NLS) at the C-terminus. The company was founded in 1999 and is based in Quebec, Canada.Feldan Therapeutics operates as a biopharmaceutical development company that specializes in intracellular delivery of therapeutic compounds into cells. It offers membrane interaction that interacts with the membrane to initiate permeabilization process, endosomal leakage permeabilization process. Feldan Shuttle delivers therapeutic compounds inside cells, enabling the development of next-generation therapies such as peptide-based, fast degradation, peptide, and protein delivery, and avoiding endosomal entrapment; and facilitating intracellular pathway modulation such as repressing pathogenic pathways, supplying missing proteins, and rewriting impaired genes. The company was incorporated in 2007 and is based in Québec, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 9.8
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 26
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Michaud, Francois-Thomas 
Co-Founder, Chief Executive Officer and Director
Benchabane, Meriem 
Marketing and Business Development Director

Key Board Members
Name
Title
Cyr, Benoit 
Chairman of the Board
Michaud, Francois-Thomas 
Co-Founder, Chief Executive Officer and Director
De Serres, Jean 
Independent Director
Dukes, Iain D.
Independent Director
Gries, Jean-Michel 
Scientific Advisory Board Member
Harland, Xavier 
Independent Director
Huh, Jinsung 
Director
Kim, Hyun-Ki 
Director
Mazzo, David J.
Independent Director
Morand, Peter
Independent Director
Rhodes, Christopher A.
Scientific Advisory Board Member
Sansregret, Jean-Luc
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
2666 Boulevard du Parc Technologique Suite 290 | Quebec, QC | G1P 4S6 | Canada
Phone: 418-872-7277   Fax: 418-872-7007

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Amgen Ventures
Jun-13-2023
Unknown
-
Series B
Investissement Québec, Investment Arm
Jun-13-2023
Unknown
-
Series B
Centre for Commercialization of Regenerative Medicine
Mar-08-2023
Unknown
-
Bridge
Consortium Québécois sur la Découverte du Médicament
Mar-08-2023
Unknown
-
Bridge
Asahi Kasei Corporate Venture Capital
Sep-18-2018
Unknown
-
Series A

Prior Investors
CQVB, Investment Arm


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-13-2023
Jun-13-2023
Private Placement
Target
Feldan Bio Inc.
Green Cross Holdings Corporation (KOSE:A005250),Amgen Ventures,Investissement Québec, Investment Arm

16.50
Mar-08-2023
Mar-08-2023
Private Placement
Target
Feldan Bio Inc.
Green Cross Holdings Corporation (KOSE:A005250),Consortium Québécois sur la Découverte du Médicament,Centre for Commercialization of Regenerative Medicine

-
Sep-18-2018
Nov-27-2018
Private Placement
Target
Feldan Bio Inc.
Anges Québec,Stonebridge Ventures Inc. (KOSDAQ:A330730),Green Cross Holdings Corporation (KOSE:A005250),Asahi Kasei Corporate Venture Capital Buyer Funds:Anges Québec Capital Fund

10.39
Mar-23-2015
Mar-23-2015
Private Placement
Target
Feldan Bio Inc.
Anges Québec,FIER Succès S.E.C. Buyer Funds:Anges Québec Capital Fund

0.98
Aug-29-2013
Aug-29-2013
Private Placement
Target
Feldan Bio Inc.
Anges Québec,FIER Succès S.E.C. Buyer Funds:Anges Québec Capital Fund

0.50
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-11-2023
Company Conference Presentations
Feldan Bio Inc. Presents at RNA Editing Summit 2023, Jul-11-2023
Jun-13-2023
Private Placements
Feldan Bio Inc. announced that it has received $16.5 million in funding from Amgen Ventures, Investissement Québec, Investment Arm, Green Cross Holdings Corporation and other investors
Apr-18-2023
Company Conference Presentations
Feldan Bio Inc. Presents at 13th Annual BioPartnering Conference, Apr-18-2023
Apr-17-2023
Company Conference Presentations
Feldan Bio Inc. Presents at BioNJ BioPartnering Conference – SciSafe Services, Apr-17-2023
Mar-08-2023
Private Placements
Feldan Bio Inc. announced that it has received funding from Green Cross Holdings Corporation, Consortium Québécois sur la Découverte du Médicament, Centre for Commercialization of Regenerative Medicine


Advisors
Private Placement Advisors
McCarthy Tétrault LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 01:14 AM
Feldan Bio Inc.
Feldan Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
18
GlobalData

Sep 14, 2023 09:28 PM
Feldan Bio Inc.
Feldan Therapeutics Inc
Reports
53
GlobalData

Aug 23, 2023 06:48 AM
Feldan Bio Inc.
Feldan Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
24
GlobalData

Jun 19, 2023 05:39 AM
Feldan Bio Inc.
Feldan Therapeutics Inc
Reports
52
GlobalData

Jun 09, 2023 12:21 AM
Feldan Bio Inc.
Feldan Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

May 17, 2023 05:39 AM
Feldan Bio Inc.
Feldan Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Mar 15, 2023 01:41 AM
Feldan Bio Inc.
Feldan Therapeutics Inc
Reports
50
GlobalData

Mar 10, 2023 02:58 AM
Feldan Bio Inc.
Feldan Therapeutics Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Feb 10, 2023 04:20 AM
Feldan Bio Inc.
Feldan Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
23
GlobalData

Dec 28, 2022 02:14 AM
Feldan Bio Inc.
Feldan Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
27


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Cyr, Benoit 
Chairman of the Board
418-872-7277
418-872-7007

Michaud, Francois-Thomas 
Co-Founder, Chief Executive Officer and Director
418-872-7277
418-872-7007

De Serres, Jean 
Independent Director
418-872-7277
418-872-7007

Dukes, Iain D.
Independent Director
418-872-7277
418-872-7007

Gries, Jean-Michel 
Scientific Advisory Board Member
418-872-7277
418-872-7007

Harland, Xavier 
Independent Director
418-872-7277
418-872-7007

Huh, Jinsung 
Director
418-872-7277
418-872-7007

Kim, Hyun-Ki 
Director
418-872-7277
418-872-7007

Mazzo, David J.
Independent Director
418-872-7277
418-872-7007
dmazzo@caladrius.com
Morand, Peter
Independent Director
418-872-7277
418-872-7007
-
Rhodes, Christopher A.
Scientific Advisory Board Member
418-872-7277
418-872-7007

Sansregret, Jean-Luc
Independent Director
418-872-7277
418-872-7007
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Michaud, Francois-Thomas 
Co-Founder, Chief Executive Officer and Director
418-872-7277
418-872-7007

Benchabane, Meriem 
Marketing and Business Development Director
418-872-7277
418-872-7007

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
